New  ||| S:0 E:4 ||| JJ
oral  ||| S:4 E:9 ||| JJ
anticoagulants ||| S:9 E:23 ||| NN
:  ||| S:23 E:25 ||| :
recommendations ||| S:25 E:40 ||| NNS
,  ||| S:40 E:42 ||| ,
precautions  ||| S:42 E:54 ||| NNS
and  ||| S:54 E:58 ||| CC
perspectives  ||| S:58 E:71 ||| NN
for  ||| S:71 E:75 ||| IN
use  ||| S:75 E:79 ||| NN
In  ||| S:79 E:82 ||| IN
phase  ||| S:82 E:88 ||| NN
III  ||| S:88 E:92 ||| NNP
studies ||| S:92 E:99 ||| NNS
,  ||| S:99 E:101 ||| ,
some  ||| S:101 E:106 ||| DT
oral  ||| S:106 E:111 ||| JJ
inhibitors  ||| S:111 E:122 ||| NN
of  ||| S:122 E:125 ||| IN
both  ||| S:125 E:130 ||| DT
thrombin  ||| S:130 E:139 ||| NN
( ||| S:139 E:140 ||| -LRB-
dabigatran  ||| S:140 E:151 ||| FW
etexilate ||| S:151 E:160 ||| FW
)  ||| S:160 E:162 ||| -RRB-
and  ||| S:162 E:166 ||| CC
activated  ||| S:166 E:176 ||| JJ
factor  ||| S:176 E:183 ||| NN
X  ||| S:183 E:185 ||| NN
( ||| S:185 E:186 ||| -LRB-
rivaroxaban ||| S:186 E:197 ||| UH
,  ||| S:197 E:199 ||| ,
apixaban ||| S:199 E:207 ||| CD
)  ||| S:207 E:209 ||| -RRB-
have  ||| S:209 E:214 ||| VBP
been  ||| S:214 E:219 ||| VBN
employed  ||| S:219 E:228 ||| VBN
as  ||| S:228 E:231 ||| IN
new  ||| S:231 E:235 ||| JJ
anticoagulant  ||| S:235 E:249 ||| JJ
drugs  ||| S:249 E:255 ||| NNS
in  ||| S:255 E:258 ||| IN
patients  ||| S:258 E:267 ||| NNS
with  ||| S:267 E:272 ||| IN
atrial  ||| S:272 E:279 ||| JJ
fibrillation  ||| S:279 E:292 ||| NN
or  ||| S:292 E:295 ||| CC
acute  ||| S:295 E:301 ||| JJ
coronary  ||| S:301 E:310 ||| JJ
syndromes ||| S:310 E:319 ||| NN
.  ||| S:319 E:321 ||| .
Such  ||| S:321 E:326 ||| JJ
new  ||| S:326 E:330 ||| JJ
drugs  ||| S:330 E:336 ||| NNS
have  ||| S:336 E:341 ||| VBP
overcome  ||| S:341 E:350 ||| VBN
a  ||| S:350 E:352 ||| DT
series  ||| S:352 E:359 ||| NN
of  ||| S:359 E:362 ||| IN
limitations  ||| S:362 E:374 ||| NNS
of  ||| S:374 E:377 ||| IN
the  ||| S:377 E:381 ||| DT
standard-of-care  ||| S:381 E:398 ||| JJ
warfarin ||| S:398 E:406 ||| NN
,  ||| S:406 E:408 ||| ,
and  ||| S:408 E:412 ||| CC
argue  ||| S:412 E:418 ||| VBP
for  ||| S:418 E:422 ||| IN
the  ||| S:422 E:426 ||| DT
possibility  ||| S:426 E:438 ||| NN
of  ||| S:438 E:441 ||| IN
an  ||| S:441 E:444 ||| DT
easy ||| S:444 E:448 ||| JJ
,  ||| S:448 E:450 ||| ,
widespread  ||| S:450 E:461 ||| JJ
use  ||| S:461 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
anticoagulation  ||| S:468 E:484 ||| NN
in  ||| S:484 E:487 ||| IN
vascular  ||| S:487 E:496 ||| JJ
medicine ||| S:496 E:504 ||| NN
.  ||| S:504 E:506 ||| .
However ||| S:506 E:513 ||| RB
,  ||| S:513 E:515 ||| ,
to  ||| S:515 E:518 ||| TO
this  ||| S:518 E:523 ||| DT
end ||| S:523 E:526 ||| NN
,  ||| S:526 E:528 ||| ,
we  ||| S:528 E:531 ||| PRP
need  ||| S:531 E:536 ||| VBP
information  ||| S:536 E:548 ||| NN
on  ||| S:548 E:551 ||| IN
management  ||| S:551 E:562 ||| NN
of  ||| S:562 E:565 ||| IN
bleeding  ||| S:565 E:574 ||| VBG
in  ||| S:574 E:577 ||| IN
patients  ||| S:577 E:586 ||| NNS
receiving  ||| S:586 E:596 ||| VBG
these  ||| S:596 E:602 ||| DT
drugs ||| S:602 E:607 ||| NNS
.  ||| S:607 E:609 ||| .
Dabigatran  ||| S:609 E:620 ||| JJ
etexilate ||| S:620 E:629 ||| NN
,  ||| S:629 E:631 ||| ,
rivaroxaban  ||| S:631 E:643 ||| NN
and  ||| S:643 E:647 ||| CC
apixaban  ||| S:647 E:656 ||| RB
affect  ||| S:656 E:663 ||| VB
major  ||| S:663 E:669 ||| JJ
laboratory  ||| S:669 E:680 ||| NN
tests  ||| S:680 E:686 ||| NNS
for  ||| S:686 E:690 ||| IN
clotting ||| S:690 E:698 ||| NN
.  ||| S:698 E:700 ||| .
However ||| S:700 E:707 ||| RB
,  ||| S:707 E:709 ||| ,
at  ||| S:709 E:712 ||| IN
present  ||| S:712 E:720 ||| JJ
we  ||| S:720 E:723 ||| PRP
do  ||| S:723 E:726 ||| VBP
not  ||| S:726 E:730 ||| RB
know  ||| S:730 E:735 ||| VB
whether  ||| S:735 E:743 ||| IN
and  ||| S:743 E:747 ||| CC
how  ||| S:747 E:751 ||| WRB
this  ||| S:751 E:756 ||| DT
information  ||| S:756 E:768 ||| NN
may  ||| S:768 E:772 ||| MD
be  ||| S:772 E:775 ||| VB
clinically  ||| S:775 E:786 ||| RB
useful ||| S:786 E:792 ||| JJ
.  ||| S:792 E:794 ||| .
Their  ||| S:794 E:800 ||| PRP$
high  ||| S:800 E:805 ||| JJ
cost  ||| S:805 E:810 ||| NN
is  ||| S:810 E:813 ||| VBZ
another  ||| S:813 E:821 ||| DT
major  ||| S:821 E:827 ||| JJ
issue ||| S:827 E:832 ||| NN
,  ||| S:832 E:834 ||| ,
and  ||| S:834 E:838 ||| CC
newer  ||| S:838 E:844 ||| JJR
pharmacoeconomic  ||| S:844 E:861 ||| JJ
studies  ||| S:861 E:869 ||| NNS
are  ||| S:869 E:873 ||| VBP
needed  ||| S:873 E:880 ||| VBN
to  ||| S:880 E:883 ||| TO
evaluate  ||| S:883 E:892 ||| VB
their  ||| S:892 E:898 ||| PRP$
cost-effectiveness  ||| S:898 E:917 ||| JJ
ratio  ||| S:917 E:923 ||| NN
vs  ||| S:923 E:926 ||| NN
warfarin ||| S:926 E:934 ||| NN
.  ||| S:934 E:936 ||| .
